Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMD3C21)

Drug Name

GBT021601 Drug Info

Synonyms

Osivelotor; GBT-601; GBT021601; GBT-021601; 2417955-18-9; osivelotor [INN]; 2-hydroxy-6-({(3S)-4-[2-(2-hydroxyethyl)pyridine-3-carbonyl]morpholin-3-yl}methoxy)benzaldehyde; 2-hydroxy-6-[[(3S)-4-[2-(2-hydroxyethyl)pyridine-3-carbonyl]morpholin-3-yl]methoxy]benzaldehyde; SCHEMBL21957946; GTPL12856; UK749B4S16; example 8 [US20210047309]; HY-148788; CS-0641066; 2-hydroxy-6-{[(3S)-4-{[2-(2-hydroxyethyl)pyridin-3- yl]carbonyl}morpholin-3-yl]methoxy}benzaldehyde

Indication

Disease Entry	ICD 11	Status	REF
Sickle-cell disorder	3A51	Phase 2/3	[1]

Cross-matching ID

PubChem CID: 146567655
TTD Drug ID: DMD3C21

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Hemoglobin (HB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Voxelotor	DMCS6M5	Sickle-cell disorder	3A51	Approved	[3]
Iron	DMAP8MV	Anemia of prematurity		Approved	[4]
Iron Dextran	DM5OY70	Iron-deficiency anemia	3A00	Approved	[4]
PolyHeme	DMV8EXG	Blood forming organ disorder	JB64.1	Phase 3	[5]
Efaproxyn	DMX7BM4	Lung cancer	2C25.0	Phase 3	[6]
Hemoglobin raffimer	DMMTL7V	Anemia	3A00-3A9Z	Phase 2/3	[7]
FBS-0701	DMR3952	Iron overload disease	5C64.10	Phase 2	[8]
HQK-1001	DM7QUN0	Beta thalassemia	3A50.2	Phase 2	[9]
5-hydroxymethyl-2-furfural	DMPFVJB	Anemia	3A00-3A9Z	Phase 2	[10]
OXY-111A	DMTH75R	Cardiovascular disease	BA00-BE2Z	Phase 1/2	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Hemoglobin (HB)	TTQO71U	HBA_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT05632354) An Open-label Extension Study to Evaluate the Long-term Safety of GBT021601 Administered to Participants With Sickle Cell Disease Who Have Participated in a GBT021601 Clinical Trial. U.S.National Institutes of Health.
2	GBT021601 improves red blood cell health and the pathophysiology of sickle cell disease in a murine model. Br J Haematol. 2023 Jul;202(1):173-183.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
4	Efficacy and safety of total dose infusion of low molecular weight iron dextran in the treatment of iron deficiency anemia during pregnancy. J Coll Physicians Surg Pak. 2008 Jul;18(7):424-7.
5	Blood substitutes- the polyheme trials. Mcgill J Med. 2008 January; 11(1): 59-65.
6	Increased oxygenation of intracranial tumors by efaproxyn (efaproxiral), an allosteric hemoglobin modifier: In vivo EPR oximetry study. Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1503-9.
7	Use of hemoglobin raffimer for postoperative life-threatening anemia in a Jehovah's Witness. Can J Anaesth. 2005 Apr;52(4):369-73.
8	A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res. 2009 Dec 1;15(23):7144-52.
9	A phase 2 study of HQK-1001, an oral fetal haemoglobin inducer, in beta-thalassaemia intermedia. Br J Haematol. 2014 Feb;164(3):456-8.
10	5-hydroxymethyl-2-furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells. Br J Haematol. 2005 Feb;128(4):552-61.
11	Modulating the oxygen affinity of human fetal haemoglobin with synthetic allosteric modulators. Br J Haematol. 1998 Sep;102(5):1165-71.